We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Ergomed Plc | LSE:ERGO | London | Ordinary Share | GB00BN7ZCY67 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1,346.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMERGO
RNS Number : 7548A
Ergomed plc
14 September 2018
PRESS RELEASE
FOR IMMEDIATE RELEASE
Notice of Interim Results
London, UK - 14 September 2018: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, will announce its interim results for the six months ended 30 June 2018 on Wednesday 19(th) September 2018.
Stephen Stamp, Chief Executive Officer and Stuart Jackson, Chief Financial Officer, will host a presentation and conference call for analysts at 8:30am BST on the day of the results at the offices of Numis Securities, The London Stock Exchange Building, 10 Paternoster Square, London, EC4M 7LT.
ENDS
Enquiries:
Ergomed plc Tel: +44 (0) 1483 503 205 Stephen Stamp (Chief Executive Officer) Stuart Jackson (Chief Financial Officer) Numis Securities Limited Tel: +44 (0) 20 7260 1000 Michael Meade / Freddie Barnfield (Nominated Adviser) James Black (Joint Broker) Consilium Strategic Communications - Tel: +44 (0) 20 3709 5700 for UK enquiries Chris Gardner / Mary-Jane Elliott ergomed@consilium-comms.com Matthew Neal / Olivia Manser MC Services - for Continental European Tel: +49 211 5292 5222 enquiries Anne Hennecke
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NORDBGDCUBBBGIX
(END) Dow Jones Newswires
September 14, 2018 02:01 ET (06:01 GMT)
1 Year Ergomed Chart |
1 Month Ergomed Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
